Hemiplegia adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 8,218 adverse event reports that record the MedDRA preferred term Hemiplegia. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 350 reports in the 12 months to June 2026 and 388 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,169 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 350 (under 0.1%) record this term. Reports for patients 75 and over were 16.6% of the reports that record this term and 9.5% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 141 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Hemiplegia name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		209
Acetylsalicylic Acid		155
Actilyse		32
Albuterol	beta2-Adrenergic agonist	27
Albuterol sulfate	beta2-Adrenergic agonist	28
Aliskiren	Renin inhibitor	147
Aliskiren hemifumarate	Renin inhibitor	167
Altace		198
Alteplase		33
Amlodipine	Calcium channel blocker	200
Amlodipine Besilate		31
Amlodipine besylate	Dihydropyridine calcium channel blocker	156
Ampyra	Potassium channel blocker	41
Arixtra	Factor Xa inhibitor	37
Aspirin	Nonsteroidal anti-inflammatory drug	366
Atacand	Angiotensin 2 receptor blocker	125
Atorvastatin		49
Atorvastatin calcium	HMG-CoA reductase inhibitor	30
Avandia		94
Avastin	Vascular endothelial growth factor inhibitor	70
Avonex	Interferon beta	137
Bevacizumab	Vascular endothelial growth factor inhibitor	25
Bextra		25
Bisoprolol	beta-Adrenergic blocker	173
Bisoprolol fumarate	beta-Adrenergic blocker	42
Calcium carbonate	Blood coagulation factor	155
Candesartan	Angiotensin 2 receptor blocker	120
Candesartan cilexetil	Angiotensin 2 receptor blocker	82
Carboplatin	Platinum-based drug	30
Celebrex	Nonsteroidal anti-inflammatory drug	84
Cisplatin	Platinum-based drug	43
Clobazam	Benzodiazepine	33
Clonazepam	Benzodiazepine	38
Clopidogrel	P2Y12 platelet inhibitor	81
Copaxone		45
Cosentyx	Interleukin-17A antagonist	215
Coumadin		34
Cyclophosphamide	Alkylating drug	63
Cytarabine	Nucleoside metabolic inhibitor	33
Dexamethasone	Corticosteroid	68
Diovan	Angiotensin 2 receptor blocker	101
Diphenhydramine	Histamine-1 receptor antagonist	54
Diphenhydramine hydrochloride	Histamine-1 receptor antagonist	127
Eliquis	Factor Xa inhibitor	83
Enbrel	Tumor necrosis factor blocker	71
Entresto	Angiotensin 2 receptor blocker	40
Ergocalciferol	Provitamin D2 compound	186
Esomeprazole	Proton pump inhibitor	155
Esomeprazole magnesium	Proton pump inhibitor	150
Esomeprazole Magnesium Naproxen		73
Esomeprazole magnesium trihydrate		31
Esomeprazole sodium	Proton pump inhibitor	31
Etoposide	Topoisomerase inhibitor	35
Exelon	Cholinesterase inhibitor	30
Forteo	Parathyroid hormone analog	33
Furosemide	Loop diuretic	43
Gabapentin	Anti-epileptic agent	36
Gilenya	Sphingosine 1-phosphate receptor modulator	141
Gliadel	Alkylating drug	35
Gliclazide		171
Glucophage		25
Gravol	Histamine-1 receptor antagonist	163
Heparin		48
Humalog	Insulin analog	42
Humira		206
Irbesartan	Angiotensin 2 receptor blocker	288
Januvia	Dipeptidyl peptidase 4 inhibitor	266
Keppra		42
Kesimpta	CD20-directed cytolytic antibody	31
Lantus	Insulin analog	30
Lasix	Loop diuretic	60
Levothyroxine		47
Levothyroxine sodium	l-Thyroxine	131
Lipitor	HMG-CoA reductase inhibitor	260
Lisinopril	Angiotensin converting enzyme inhibitor	156
Lyrica		70
Metformin	Biguanide	263
Metformin hydrochloride	Biguanide	139
Methotrexate	Folate analog metabolic inhibitor	304
Methylprednisolone	Corticosteroid	87
Methylprednisolone sodium succinate	Corticosteroid	154
Mianserin Hydrochloride		31
Morphine	Opioid agonist	104
Morphine sulfate	Opioid agonist	106
Mycophenolate mofetil	Antimetabolite immunosuppressant	41
Naproxen	Nonsteroidal anti-inflammatory drug	30
Nexium	Proton pump inhibitor	65
Nexium 24HR	Proton pump inhibitor	36
Nitroglycerin	Nitrate vasodilator	37
Norvasc	Calcium channel blocker	26
Ocrevus	CD20-directed cytolytic antibody	32
Omeprazole	Proton pump inhibitor	107
Ondansetron	Serotonin-3 receptor antagonist	124
Ondansetron hydrochloride	Serotonin-3 receptor antagonist	53
Pantoprazole	Proton pump inhibitor	27
Paracetamol		35
Pipamperone		42
Plavix	P2Y12 platelet inhibitor	104
Polyethylene glycol 3350	Osmotic laxative	25
Pradaxa	Direct thrombin inhibitor	187
Prednisolone	Corticosteroid	85
Prednisolone sodium phosphate	Corticosteroid	27
Prednisone	Corticosteroid	228
Prochlorperazine	Phenothiazine	169
Propranolol	beta-Adrenergic blocker	32
Ramipril	Angiotensin converting enzyme inhibitor	146
Rasilez		87
Rebif	Interferon beta	62
Remicade	Tumor necrosis factor blocker	28
Revlimid	Thalidomide analog	34
Rituxan	CD20-directed cytolytic antibody	37
Rituximab	CD20-directed cytolytic antibody	213
Rivaroxaban	Factor Xa inhibitor	51
Rivotril		35
Salmeterol xinafoate	beta2-Adrenergic agonist	30
Serevent Diskus		39
Simvastatin	HMG-CoA reductase inhibitor	64
Sitagliptin phosphate	Dipeptidyl peptidase 4 inhibitor	31
Skyrizi	Interleukin-23 antagonist	29
Synthroid	l-Thyroxine	131
Tacrolimus	Calcineurin inhibitor immunosuppressant	47
Tasigna	Kinase inhibitor	37
Tecfidera		104
Tegretol	Mood stabilizer	25
Temodal		25
Topiramate		26
Trihexyphenidyl hydrochloride		29
Tums Ultra		27
Tysabri	Integrin receptor antagonist	142
Verapamil hydrochloride	Calcium channel blocker	26
Vincristine		25
Vioxx		58
Warfarin	Vitamin K antagonist	30
Xarelto	Factor Xa inhibitor	278
Yasmin		45
Yaz		52
Zestril	Angiotensin converting enzyme inhibitor	67
Zocor	HMG-CoA reductase inhibitor	34
Zofran		48
Zolpidem	gamma-Aminobutyric acid A receptor positive modulator	96
Zopiclone		55

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 47 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Hemiplegia name, in order of name
Class	Reports with this term
Alkylating drug	121
Angiotensin 2 receptor blocker	822
Angiotensin converting enzyme inhibitor	369
Anti-epileptic agent	85
Antimetabolite immunosuppressant	50
Atypical antipsychotic	83
Benzodiazepine	81
beta-Adrenergic blocker	290
beta2-Adrenergic agonist	89
Biguanide	407
Blood coagulation factor	162
Calcineurin inhibitor immunosuppressant	82
Calcium channel blocker	252
CD20-directed cytolytic antibody	313
Corticosteroid	692
Dihydropyridine calcium channel blocker	165
Dipeptidyl peptidase 4 inhibitor	309
Direct thrombin inhibitor	192
Factor Xa inhibitor	474
Folate analog metabolic inhibitor	345
gamma-Aminobutyric acid A receptor positive modulator	106
Histamine-1 receptor antagonist	366
HMG-CoA reductase inhibitor	427
Insulin analog	147
Integrin receptor antagonist	151
Interferon beta	216
Interleukin-17A antagonist	220
Kinase inhibitor	212
l-Thyroxine	264
Loop diuretic	103
Mood stabilizer	54
Nonsteroidal anti-inflammatory drug	557
Nucleoside metabolic inhibitor	96
Opioid agonist	303
P2Y12 platelet inhibitor	225
Phenothiazine	169
Platinum-based drug	92
Potassium channel blocker	56
Programmed death Receptor-1 blocking antibody	53
Proton pump inhibitor	616
Provitamin D2 compound	188
Renin inhibitor	147
Serotonin reuptake inhibitor	99
Serotonin-3 receptor antagonist	177
Sphingosine 1-phosphate receptor modulator	150
Tumor necrosis factor blocker	133
Vascular endothelial growth factor inhibitor	133

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Hemiplegia, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Hemiplegia
Age	Reports	Share
Under 2	32	0.4%
2 to 11	113	1.4%
12 to 17	118	1.4%
18 to 44	1,136	13.8%
45 to 64	2,014	24.5%
65 to 74	1,346	16.4%
75 and over	1,368	16.6%
Age not given	2,091	25.4%

Sex of the patient in the reports that record Hemiplegia
Sex	Reports	Share
Female	4,337	52.8%
Male	3,392	41.3%
Unknown or not given	489	6%

Age and sex are as the report gives them. 30.2% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Hemiplegia: adverse event reports that record this term. https://reportedreactions.com/reaction/hemiplegia/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Hemiplegia mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page